Abstract
Dengue viruses (DENV) are endemic in the US territories of Puerto Rico, American Samoa, and the US Virgin Islands, with focal outbreaks also reported in the states of Florida and Hawaii. However, little is known about the intensity of dengue virus transmission over time and how dengue viruses have shaped the level of immunity in these populations, despite the importance of understanding how and why levels of immunity against dengue may change over time. These changes need to be considered when responding to future outbreaks and enacting dengue management strategies, such as guiding vaccine deployment. We used catalytic models fitted to case surveillance data stratified by age from the ArboNET national arboviral surveillance system to reconstruct the history of recent dengue virus transmission in Puerto Rico, American Samoa, US Virgin Islands, Florida, Hawaii, and Guam. We estimated average annual transmission intensity (i.e., force of infection) of DENV between 2010 and 2019 and the level of seroprevalence by age group in each population. We compared models and found that treating all reported cases as secondary infections generally fit the surveillance data better than models considering cases as primary infections. Using the secondary case model, we found that force of infection was highly heterogeneous between jurisdictions and over time within jurisdictions, ranging from 0.00003 (95% CI: 0.00002–0.0004) in Florida to 0.08 (95% CI: 0.044–0.14) in American Samoa during the 2010–2019 period. For early 2020, we estimated that seropositivity in 10 year-olds ranged from 0.09% (0.02%–0.54%) in Florida to 56.3% (43.7%–69.3%) in American Samoa. In the absence of serological data, age-specific case notification data collected through routine surveillance combined with mathematical modeling are powerful tools to monitor arbovirus circulation, estimate the level of population immunity, and design dengue management strategies.
Author Summary Viruses transmitted by Aedes mosquitoes are a substantial public health burden globally. In the US, the increasing number of outbreaks in recent decades and the co-circulation of the four dengue viruses present a risk of experiencing sequential infections, which can result in more severe disease. However, reported cases only represent a proportion of all infections, so the intensity of dengue circulation in US jurisdictions and the level of population immunity are largely unknown. Combining dengue surveillance data stratified by age with mathematical models enables direct estimation of transmission intensity and previous exposure. We found that dengue virus transmission intensity was highest in American Samoa and Puerto Rico. The US Virgin Islands also showed patterns of endemic transmission, while Hawaii and Guam present more sporadic outbreak profiles. These estimates can help improve risk assessment in these locations and guide interventions to the populations who most need them.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by an appointment to S.K. to the Research Participation Program at the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ArboNET surveillance data is available to researchers upon request.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The ArboNET surveillance data is available to researchers upon request. Code used to run the current analysis are available in the GitHub repository, ...
